The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Janus Kinase vs. TNF Inhibitors: The Context for Venous Thromboembolism Risk with RA Treatments

Janus Kinase vs. TNF Inhibitors: The Context for Venous Thromboembolism Risk with RA Treatments

October 7, 2020 • By Larry Beresford

  • Tweet
  • Email
Print-Friendly Version / Save PDF

An observational study of the relative risk for venous thromboembolism events from two immunotherapeutic modalities used to treat rheumatoid arthritis (RA) finds a numerical—but not statistically significant—increase of venous thromboembolism from tofacitinib when compared with tumor necrosis factor (TNF) inhibitors.1 In 2012, tofacitinib became the first Janus kinase inhibitor (jakinib) approved by the U.S. Food & Drug Administration (FDA) to treat RA. But research into high-dose baricitinib therapy for RA and a post-marketing study of tofacitinib and TNF inhibitors to assess cardiovascular risk have raised questions about the association of jakinibs with venous thromboembolism.2-4

You Might Also Like
  • Janus Kinase Inhibitors Represent New Tool to Slow Rheumatoid Arthritis
  • Researchers Give Update on Janus Kinase (JAK) Inhibitors
  • Where Will Kinase Inhibitors Fit into the RA Treatment Mix?

Janus kinases are believed to play an important role in inflammatory processes by signaling more than 50 cytokines and growth factors. Small-molecule jakinibs, starting with tofacitinib and then baricitinib, approved by the FDA for RA in 2018, have expanded treatment options. They offer a novel treatment modality with the potential to become as important as TNF inhibitors in treating RA, says Rishi J. Desai, MS, PhD, assistant professor of medicine at Harvard Medical School, Boston, and an associate epidemiologist in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital, Boston. He is the lead author of the new study.

Dr. Desai

Tofacitinib is a targeted, synthetic, disease-modifying anti-rheumatic drug (DMARD) that inhibits components of the intracellular inflammatory signaling cascade. Its oral administration offers obvious advantages for ease of use, especially because treatment may be needed for a patient’s lifetime. An important concern raised with jakinibs is the risk for venous thromboembolism, even though that happens fairly infrequently, Dr. Desai says.

Tofacitinib has also been studied to treat Crohn’s disease, ulcerative colitis and alopecia areata. Other promising jakinibs under investigation for RA and other autoimmune diseases include filgotinib, which is under investigation for psoriatic arthritis and RA; upadacitinib, which is FDA-approved for RA; abrocitinib, which targets JAK 1; and Pfizer’s JAK 3 inhibitor PF-06651600.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Is Venous Thromboembolism a Class Effect?
“We were curious: Was the venous thromboembolism risk a class effect with JAK inhibitors? We decided to look to population-based studies to get at this question,” Dr. Desai tells The Rheumatologist.

The researchers drew on two, large-population, data sources commonly used in the study of RA, Truven Health Analytics’ proprietary Market Scan Database for the years 2012–16 and the Medicare Parts A, B and D database for the years 2012–15. Researchers performed separate analyses of each database and then a combined analysis.

Pages: 1 2 3 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: JAK inhibitors, jakinib, Rheumatoid Arthritis (RA), TNF inhibitors, Tofacitinib

You Might Also Like:
  • Janus Kinase Inhibitors Represent New Tool to Slow Rheumatoid Arthritis
  • Researchers Give Update on Janus Kinase (JAK) Inhibitors
  • Where Will Kinase Inhibitors Fit into the RA Treatment Mix?
  • Small Increased Risk for CIN & Cervical CA with TNF Inhibitors

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)